Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Profit After Tax (2020 - 2026)

Immuneering's Profit After Tax history spans 7 years, with the latest figure at -$13.5 million for Q1 2026.

  • On a quarterly basis, Profit After Tax rose 10.54% to -$13.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$54.4 million, a 11.87% increase, with the full-year FY2025 number at -$56.0 million, up 8.21% from a year prior.
  • Profit After Tax came in at -$13.5 million for Q1 2026, down from -$11.6 million in the prior quarter.
  • The five-year high for Profit After Tax was -$11.5 million in Q2 2022, with the low at -$18.1 million in Q4 2024.
  • Historically, Profit After Tax has averaged -$13.8 million across 5 years, with a median of -$13.6 million in 2023.
  • Biggest five-year swings in Profit After Tax: tumbled 107.02% in 2022 and later surged 35.85% in 2025.
  • Year by year, Profit After Tax stood at -$13.2 million in 2022, then fell by 13.88% to -$15.1 million in 2023, then fell by 19.68% to -$18.1 million in 2024, then soared by 35.85% to -$11.6 million in 2025, then fell by 16.24% to -$13.5 million in 2026.
  • Business Quant data shows Profit After Tax for IMRX at -$13.5 million in Q1 2026, -$11.6 million in Q4 2025, and -$15.0 million in Q3 2025.